Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia Inc. has changed its corporate name to Hyperion DeFi, Inc. and shifted its public-company updates toward a cryptocurrency treasury reserve strategy centered on HYPE, the native token of the Hyperliquid protocol. Recurring news includes HYPE acquisitions, staking and validator activity, digital-asset treasury governance, and related financing actions.
The company’s legacy ophthalmic technology disclosures continue to reference the Optejet topical ophthalmic medication dispensing platform, including development work on the user-filled device for use with topical ophthalmic liquids. Company updates also cover capital-structure changes, debt amendments, governance matters, and Nasdaq trading under the HYPD symbol following the name change.
Eyenovia, Inc. (NASDAQ: EYEN), a clinical-stage ophthalmic biopharmaceutical firm, is set to release its financial results for Q1 2020 on May 13, 2020, post-market close. Dr. Sean Ianchulev, CEO, alongside CFO John Gandolfo and VP Michael Rowe, will conduct a conference call at 4:45 PM ET to discuss the results. The call can be accessed by dialing 1-866-916-2921 (US) or 1-210-874-7771 (International), using conference code 4397339. The event will also be streamed live on Eyenovia's investor relations webpage and archived for one year.